WallStreetZenWallStreetZen

NASDAQ: COLL
Collegium Pharmaceutical Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

COLL past earnings growth

How has COLL's earnings growth performed historically?
Company
N/A
Industry
25.83%
Market
53.53%
COLL's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
COLL's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

COLL past revenue growth

How has COLL's revenue growth performed historically?
Company
7.39%
Industry
37.42%
Market
16.91%
COLL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
COLL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
COLL's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

COLL earnings and revenue history

Current Revenue
$576.7M
Current Earnings
$99.9M
Current Profit Margin
17.3%

COLL Return on Equity

Current Company
49.1%
Current Industry
10.2%
Current Market
33.8%
COLL's Return on Equity (49.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when COLL announces earnings.

COLL Return on Assets

Current Company
8.9%
Current Industry
3.6%
COLL is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

COLL Return on Capital Employed

Current Company
36.2%
Current Industry
10.9%
COLL has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

COLL vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
COLL$576.65M$363.60M$99.89M+14.49%-14.87%
ANIP$538.95M$118.65M$25.39M+20.17%-4.43%
EVON/AN/AN/A+99.41%N/A
INDV$1.15B-$126.00M-$141.00M+14.36%N/A
EOLS$237.26M-$29.60M-$53.21M+152.51%N/A
View Top Pharmaceutical Stocks

COLL earnings dates

Next earnings date
Nov 5, 2024

Collegium Pharmaceutical Earnings & Revenue FAQ

What were COLL's earnings last quarter?

On Invalid Date, Collegium Pharmaceutical (NASDAQ: COLL) reported Q2 2024 earnings per share (EPS) of $0.60, up 57.89% year over year. Total Collegium Pharmaceutical earnings for the quarter were $19.61 million. In the same quarter last year, Collegium Pharmaceutical's earnings per share (EPS) was $0.38.

If you're new to stock investing, here's how to buy Collegium Pharmaceutical stock.

What was COLL's earnings growth in the past year?

As of Q3 2024, Collegium Pharmaceutical's earnings has grown year over year. Collegium Pharmaceutical's earnings in the past year totalled $99.89 million.

What is COLL's earnings date?

Collegium Pharmaceutical's earnings date is Invalid Date. Add COLL to your watchlist to be reminded of COLL's next earnings announcement.

What was COLL's revenue last quarter?

On Invalid Date, Collegium Pharmaceutical (NASDAQ: COLL) reported Q2 2024 revenue of $145.28 million up 7.18% year over year. In the same quarter last year, Collegium Pharmaceutical's revenue was $135.55 million.

What was COLL's revenue growth in the past year?

As of Q3 2024, Collegium Pharmaceutical's revenue has grown 7.39% year over year. This is 30.02 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 37.42%. Collegium Pharmaceutical's revenue in the past year totalled $576.65 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.